Paul Geyer

Healthtech Seed Fund and Growth Accelerator Lead a venture capital investment program focused on growing digital health companies at the intersection of health, life sciences, and technology. Oversee investment strategy, portfolio management, and hands-on support for 15+ startups, investing over $20mil Managed The GENERATOR, a rent-free startup hub providing workspace, expert programming, and community for early-stage healthtech founders. Mentor founders on fundraising, business development, and governance, accelerating company growth and job creation.

The Geyer Family Office manages the Investments, Finances, Legacy and Philanthropic pursuits of the Geyer Family

Eupraxia Pharmaceuticals Inc. is a drug delivery technology company that specializes in taking existing drugs and making them targeted, long lasting, safer and more effective. Our disruptive technology in injectable drug delivery improves existing drug efficacy, patient compliance and safety in therapies for the most prevalent diseases affecting patients across the globe. We have extensive pre-clinical data demonstrating our ability to deliver drugs in a targeted fashion for up to nine months in body compartments such as the joint. We are able to do this without any of the common issues with body compartment injections such as systemic exposure. Our drugs go where we target them without affecting the body giving patients the relief they need without the side effects they don’t. With novel technology we are truly filling the void in injectable drug delivery.

As Chairman of the Board and past CEO, Paul is actively involved in setting company strategy, financial management review and building the effectiveness of Board. Participating as a member of Audit Committee and Governance and Nominating Committee. Neovasc Inc. is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Neovasc products include the Tiara™ minimally invasive mitral heart valve replacement for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. Neovasc is a Canadian Biotech company, headquartered in Vancouver, B.C. Canada, and are a publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock Exchange TSX: (NVC). Neovasc currently employs more than 180 people and as a market capitalization of over $500mil.

Paul Geyer was CEO and Chairman of Neovasc Inc. (formerly Medical Ventures Corp.), a new specialty vascular device company that developed, manufactured and markets medical devices for the rapidly growing vascular and surgical marketplace. Neovasc is comprised of the former Medical Ventures Corp., Neovasc Medical Ltd. and B-Balloon Ltd. The company's product lines included, Metricath(R) for intravascular measurement and PeriPatch(TM) surgical tissue and staple line reinforcement products. Neovasc created a development pipeline of innovative new products, and provides contract medical device development and manufacturing services. Mr. Geyer held the position of CEO and was the founder of Medical Ventures from its inception in 2001 to June 2008.

Summer Program